Skip to main content
. 2015 Mar 24;172(10):2573–2587. doi: 10.1111/bph.13088

Figure 7.

Figure 7

Roscovitine modifies the activity of DOP and MOP receptors ex vivo. Sprague-Dawley rats were injected with CFA in the plantar surface of the hindpaw. Thirty minutes before the CFA injection and every 12 h thereafter, rats were injected i.t. with vehicle or roscovitine (30 μg, i.t.). Seventy two hours after the CFA injection, rats received a single i.t. injection of Dlt II (10 μg) or DAMGO (30 ng) for 20 min, afterwards the DRGs were quickly collected and frozen in dry ice. Western blot analysis of phosphorylated ERK1/2 (pERK1 and pERK2) was performed as described in the Methods section. (A) Representative autoradiogram of ERK1/2 activation by Dlt II or DAMGO. The lower panel shows total ERK1/2. (B) Densitometric analysis of p42/p44MAPK activation. In CFA-inflamed rats, Dlt II and DAMGO increased ERK1/2 phosphorylation in vehicle-treated rats. In roscovitine-treated rats, Dlt II-induced ERK1/2 phosphorylation was reduced whereas DAMGO-induced ERK1/2 phosphorylation was increased. *P < 0.05, **P < 0.01 and ***P < 0.001. (n = 3–5 animals per group).